Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous methotrexate (MJK101) vs oral methotrexate in methotrexate-naive rheumatoid arthritis
jRCT2080224844Phase 3Completed
- Sponsor
- medac GmbH
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Subcutaneous MJK101 + oral placebo → open-label MJK101 with Oral methotrexate + subcutaneous placebo → open-label MJK101 (2 arms). Started Aug 2019; status: completed.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080224844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224844.